Thyme Care, a startup that guides cancer patients through the maze of diagnosis and treatment, has raised $125 million in Series E funding at a valuation topping $2 billion.
The Nashville-based company (founded 2020) provides value-based cancer-care navigation — partnering with health plans, employers and risk-bearing providers to help patients understand their diagnosis, find oncologists, manage care between appointments, and reach nurses and resource specialists. Its services now reach 10.5 million people across all 50 states. The round was led by JPMorgan’s Morgan Health, with Humana, CVS Health Ventures, a16z Bio + Health and others.
A new parent company
Alongside the raise, Thyme created a parent entity, Thyme Companies, to build a portfolio of independent oncology businesses — focused on accelerating biosimilar adoption and boosting clinical-trial enrollment. The first new business launches later in 2026. Robin Shah becomes executive chairman of Thyme Companies; Dr. Brad Diephuis stays on as Thyme Care CEO.
Why it matters
Cancer care is expensive, fragmented and hard to navigate. “People living with cancer have traditionally been left to coordinate care themselves and pay more along the way,” said Morgan Health CEO Dan Mendelson. Big payers backing a navigation model — and a valuation above $2 billion — signal how much appetite there is for value-based approaches that aim to improve outcomes and control the cost of oncology.